Cloudera explains how it assisted healthcare cos GSK and Celgene

More than 100 healthcare / life sciences organizations are using Cloudera for better utilizing machine learning and analytics to gain insights from data for improved patient outcomes.
Cloudera for business CIOs
The global healthcare IT market is estimated to reach $280.25 billion by 2021 at a CAGR of 15.9 percent during the forecast period of 2016 to 2021.

Healthcare and life sciences companies are using data analytics to drive biomedical research, drug discovery and development, and drive insight across clinical and health management initiatives. The aim is to cut cost and speed up market reach.

Cloudera is enabling organizations to use machine learning to integrate data sets such as EHR, genomics, imaging and more to build robust healthcare predictive analytic models and operationalize insights faster.

“The growth of AI-driven decision making in life science underscores the possibility of improving population health in a changing landscape,” Shawn Dolley, director, Management Consulting, Healthcare and Life Sciences at Cloudera, said.

Cloudera has assisted Celgene, a manufacturer of drug therapies for cancer and inflammatory disorders, to achieve a 99 percent savings in process run times for Real World Patient data analysis and 70 percent cut in operating costs by migrating legacy workloads with Cloudera.

“Using Cloudera, Celgene’s modern architecture enabled us to leapfrog our current BI and advanced analytics capabilities and improve speed to delivery of actionable insights,” said Chirayu Desai, executive director – Global Data, Information and Analytics, at Celgene.

Cloudera and several technology partners assisted GlaxoSmithKline (GSK) to develop a Big Data Information Platform that delivers a holistic view of all data within the company’s R&D division.

“Our platform, running on Cloudera, combines more than five petabytes of data spread across 2,100 data sources to give scientists an immense analytic advantage and actionable data-driven insights,” Mark Ramsey, R&D Chief Data Officer at GSK, said.